TNF and colonic disorder: Aims & Methods: SEQUENCE, an open‐label, multicenter, randomized, efficacy assessment‐blinded study, enrolled pts who previously failed ≥1 anti‐TNF therapies and had a CD Activity Index score of 220–450, Simple Endoscopic Score for CD ≥6 for ileocolonic or colonic disease (≥4 for isolated ileal disease) excluding the presence of narrowing component, plus an average (avg) daily stool frequency ≥4 and/or avg daily abdominal pain score ≥2.